If you have Medicare Part D, you can get any dose of the Wegovy pen or the Wegovy pill for a flat $50 a month starting July 1, 2026, through a new program called the Medicare GLP-1 Bridge. It’s a temporary federal demonstration run by the Centers for Medicare & Medicaid Services (CMS), and it covers Wegovy for weight management, something Medicare has never paid for before. To get the $50 price, your prescriber submits a prior authorization and confirms you meet the clinical criteria. The program is nationwide, runs through December 31, 2027, and your copay stays $50 regardless of which dose you’re on.<\/p>\n
That last point matters, because for years the only Medicare route to Wegovy ran through the cardiovascular indication. Here’s how the Bridge changes things, who qualifies, and what to weigh before you count on it.<\/p>\n
The Bridge is a short-term payment demonstration CMS authorized to give Part D beneficiaries access to GLP-1 medications for obesity. Three drugs are included: Wegovy (semaglutide) from Novo Nordisk, plus Zepbound (tirzepatide) and Foundayo (orforglipron) from Eli Lilly. All are covered for weight management at the same $50 monthly copay. For Wegovy specifically, every dose strength of both the pen and the daily pill is included.<\/p>\n
The reason a $50 price is possible: the manufacturers agreed to supply these medicines to the government at a net price of about $245 per 30-day fill, well under the roughly $1,349 list price Novo Nordisk publishes for Wegovy. You pay $50, and the program covers the gap. CMS uses a single central processor (Humana) to handle prior authorizations, claims, and pharmacy payment, so the Bridge runs alongside your plan rather than through it.<\/p>\n
Wegovy isn’t a small commitment, and the clinical case for it is well established. In the STEP 3 trial (Wadden et al., JAMA 2021), adults taking semaglutide 2.4 mg alongside intensive behavioral therapy lost markedly more weight over 68 weeks than those getting behavioral therapy alone. Access at $50 a month puts that within reach for a population that has mostly been paying full freight.<\/p>\n
Two things have to be true. First, you need to be enrolled in a Medicare drug plan in 2026, either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. Second, you have to meet clinical criteria set by CMS, which center on BMI and weight-related conditions, and your prescriber has to submit a prior authorization confirming it. CMS evaluates your BMI at the point you first started GLP-1 therapy, not at the moment of the request, so earlier treatment counts.<\/p>\n
Now the catch. The Bridge operates outside your regular Part D benefit. In practice that means the $50 you pay does not count toward your Part D deductible or your annual out-of-pocket cap (which rises to $2,100 in 2026). It also means manufacturer savings coupons can’t be applied to Bridge claims, and the low-income subsidy known as Extra Help does not reduce the $50. For most people $50 a month is a large improvement over paying cash, but if you’re a low-income beneficiary who expected Extra Help to lower it further, that protection doesn’t reach the Bridge.<\/p>\n
One more distinction: if you already get a GLP-1 through Part D for a covered medical reason, you stay on that benefit. Wegovy remains covered through standard Part D for cardiovascular risk reduction in adults with established heart disease who are overweight or obese, and that pathway counts toward your deductible and out-of-pocket cap the normal way. The Bridge is specifically the new route for the weight-management use that Part D otherwise excludes.<\/p>\n
Consider a scenario where a 67-year-old on a Part D plan has been paying cash for brand Wegovy because her plan won’t cover it for weight loss. Here’s roughly how her options stack up in 2026.<\/p>\n